Multi-arm, Non-randomized, Open-Label Phase IB Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated FGF Pathway Signaling

Trial Profile

Multi-arm, Non-randomized, Open-Label Phase IB Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated FGF Pathway Signaling

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Aug 2017

At a glance

  • Drugs FP 1039 (Primary) ; Carboplatin; Cisplatin; Docetaxel; Paclitaxel; Pemetrexed
  • Indications Mesothelioma; Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 08 Aug 2017 According to a Five Prime Therapeutics media release, clinical data from mesothelioma patients from this trial have been accepted as an oral presentation at the European Society for Medical Oncology (ESMO) 2017 Congress in September.
    • 28 Apr 2017 Planned End Date changed from 14 Apr 2017 to 28 Sep 2017.
    • 28 Apr 2017 Planned primary completion date changed from 14 Apr 2017 to 28 Sep 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top